Search for a trial

DE-escalating ocRelizumAb In cLinical and radiological stable MS

To describe the efficacy and safety of a maintenance versus induction anti-CD20 treatment strategy in pwMS.

Liraglutide for low-responders after bariatric surgery

To study the effect of Liraglutide (3.0 mg daily) on 9-month weight loss in low responders 3-months after bariatric surgery.

A Phase III Multicenter, Randomized, Double-Blind, Double-Dummy Study To Evaluate Safety And Efficacy Of Ocrelizumab In comparison with Fingolimod in Children And Adolescents With Relapsing-Remitting Multiple Sclerosis

This study has been transitioned to CTIS with ID 2023-506516-40-00 check the CTIS register for the current data. The primary efficacy objective for this study is to demonstrate non-inferiority of ocrelizumab compared with fingolimod

Towards optimal treatment for high risk prostate cancer; stereotactic pelvic radiotherapy with focal boost to the primary tumor

Determine the safety (oncological outcome and toxicity) of an comprehensive treatment combining recent advances in the treatment of high risk prostate cancer.

Dopamine synthesis capacity in patients with borderline personality disorder and auditory verbal hallucinations

What are the differences and similarities of dopamine synthesis capacity between patients with AVH and BPD, those with schizophrenia, and healthy controls?

The effect of Comprehensive Medical and Invasive Treatment strategy for patients with significant Left Anterior Descending artery disease on plaque progression

The primary objective of the registry is:To analyse coronary artery disease progression with or without coronary artery bypass grafting.The secondary objective of the registry is:To report graft patency following bypass grafting of diffusely…

ORACLE: A long-term follow-up study to evaluate the safety and durability of GT005 in participants with geographic atrophy, secondary to age-related macular degeneration treated in a Gyroscope-sponsored antecedent study.

The overall objectives of the study are to evaluate the long-term safety and durability of GT005 in participants with GA secondary to AMD who have been treated in an antecedent study.